CSS
BTAI icon

Cubist Systematic Strategies’s BioXcel Therapeutics BTAI Stock Holding History

Cubist Systematic Strategies’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-266
Closed -$1.59K – 2896
2024
Q4 		$1.59K Buy
+266
New +$2.22K ﹤0.01% 2896
2023
Q4 		– Hold
0
– -$5 – 3612
2023
Q3 		– Hold
0
– – – 3256
2022
Q4 		– Sell
-1,988
Closed -$376K – 4267
2022
Q3 		$376K Sell
1,988
-3,702
-65% -$860K ﹤0.01% 3377
2022
Q2 		$1.2M Buy
5,690
+4,841
+570% +$1.02M 0.01% 2323
2022
Q1 		$284K Buy
+849
New +$246K ﹤0.01% 2869
2021
Q4 		– Sell
-1,193
Closed -$579K – 3465
2021
Q3 		$579K Buy
+1,193
New +$525K 0.01% 1930
2021
Q2 		– Sell
-956
Closed -$660K – 2929
2021
Q1 		$660K Buy
+956
New +$769K 0.01% 1803
2020
Q4 		– Sell
-717
Closed -$498K – 2565
2020
Q3 		$498K Buy
+717
New +$538K 0.01% 1744
2019
Q4 		– Sell
-13
Closed -$1K – 2413
2019
Q3 		$1K Buy
+13
New +$2.05K ﹤0.01% 2174
2018
Q4 		– Sell
-46
Closed -$6K – 2063
2018
Q3 		$6K Sell
46
-81
-64% -$12K ﹤0.01% 1832
2018
Q2 		$19K Buy
+127
New +$19.4K ﹤0.01% 1705

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Cubist Systematic Strategies's BTAI Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 266 shares — an estimated $1.59K sold.

Cubist Systematic Strategies first reported a position in BTAI in Q2 2018 and held it in 10 quarters. The position peaked at $1.2M in Q2 2022. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 266 BioXcel Therapeutics shares in Q1 2025, an estimated $1.59K.
  • Cubist Systematic Strategies first reported a position in BioXcel Therapeutics in Q2 2018 and held it in 10 quarters.
  • Cubist Systematic Strategies's BioXcel Therapeutics position peaked at $1.2M in Q2 2022.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.